In that study, hsEVs were found to improve the resistance of AD-MSCs to reactive oxygen species (ROS) and enhance their proangiogenic capacity through miR-486-5p-mediated PTEN repression, ultimately enhancing the therapeutic efficacy of AD-MSCs in CLI [54]. This evidence concerns the gene PTEN and Alzheimer disease.